MedTrace Logo

A Study of LM-168 Combined With Other Anti-tumor Treatments in Participants With Advanced Solid Tumors

NCT07669415 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2026-07-30

No results posted yet for this study

Summary

For Safety introduction phase，this study is to evaluate the safety and tolerability of LM-168 in combination with other anti-tumor treatment regimens in participants of advanced solid tumor trials, determine the maximum tolerated dose (MTD), and explore the recommended phase II dose (RP2D).

For Dose expansion phase，this study is to evaluate the preliminary antitumor activity of LM-168 in combination with other antitumor treatment regimens in participants of advanced solid tumor trials, measured by objective response rate (ORR)

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

LM-168

Q3W,Intravenous Drip

DRUG

Tislelizumab

Q3W,Intravenous Drip

DRUG

Docetaxel injection

Q3W,Intravenous Drip

Sponsors & Collaborators

  • LaNova Medicines Limited

    lead INDUSTRY

Principal Investigators

  • lin shen · Peking University Cancer Hospital & Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-29
Primary Completion
2027-12-15
Completion
2028-12-15

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07669415 on ClinicalTrials.gov